<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02986165</url>
  </required_header>
  <id_info>
    <org_study_id>R15F10012</org_study_id>
    <nct_id>NCT02986165</nct_id>
  </id_info>
  <brief_title>Effect of Ingesting a Tomato Pomace Extract on Platelet Aggregation</brief_title>
  <acronym>Tomasa</acronym>
  <official_title>Efficacy of a Tomato Pomace Extract for Inhibiting Platelet Aggregation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro de Estudios en Alimentos Procesados</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Talca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quadram Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro de Estudios en Alimentos Procesados</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the acute and longer term effects of a tomato pomace extract on platelet
      aggregation in health subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence from human intervention trials and mechanistic studies suggests that tomato and
      tomato based products are associated with a reduction in CVD risk. The mechanism by which
      this protective effect occurs is not clearly understood but research has focused on its
      potential to modulate platelet function. This single-blind, randomized, parallel design human
      intervention trial will recruit 99 participants to consume an orange flavoured beverage
      containing different doses of a tomato pomace extract (1.0 and 2.5 g) or placebo control over
      a 5-day period. The study aims is to investigate the effects of consuming different doses of
      the tomato pomace extract on platelet aggregation. Safety and tolerability of the tomato
      pomace extracts was tested prior starting this study by undertaking a single ascending dose
      study.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline platelet aggregation at three hours</measure>
    <time_frame>Blood samples on two separate occasions (baseline and three hours post-intervention)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline platelet aggregation at 5 days</measure>
    <time_frame>Blood samples on two separate occasions (baseline and 5 days post- intervention)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 g of flavoured water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose pomace extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g pomace extract powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose pomace extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 g pomace extract powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low dose pomace extract</intervention_name>
    <description>Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.</description>
    <arm_group_label>Low dose pomace extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High dose pomace extract</intervention_name>
    <description>Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.</description>
    <arm_group_label>High dose pomace extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Apparently healthy men aged between 18 and 26 years

          -  BMI &gt;19.5 and &lt;26.0

          -  Platelet aggregation response corresponding to ≥ 65%

        Exclusion Criteria:

          -  Known tomato allergy

          -  Chronic medical conditions requiring active treatment (e.g. cardiovascular disease,
             diabetes, asthma)

          -  Gastro-intestinal disease/disorders

          -  Smokers

          -  Medically prescribed medication known to affect platelet function

          -  Self-prescribed medication known to affect platelet function (e.g. aspirin and
             non-steroidal anti-inflammatory drugs) unless participant is willing to give up.

          -  Bleeding disorders (e.g. haemophilia)

          -  Dietary supplements judged to affect study outcome

          -  Parallel participation in another research project which involves dietary intervention

          -  Blood donation within 16 weeks prior to the study

          -  Depressed or elevated blood pressure measurements (&lt;90/50 or 95/50 if symptomatic or ≥
             160/100 mmHg)

          -  Any person related to or living with any member of the study team
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Palomo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Talca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Talca</name>
      <address>
        <city>Talca</city>
        <state>Maule</state>
        <zip>3460000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Law MR, Morris JK. By how much does fruit and vegetable consumption reduce the risk of ischaemic heart disease: response to commentary. Eur J Clin Nutr. 1999 Nov;53(11):903-4.</citation>
    <PMID>10557006</PMID>
  </reference>
  <reference>
    <citation>Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002 Nov;8(11):1227-34. Review.</citation>
    <PMID>12411949</PMID>
  </reference>
  <reference>
    <citation>Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007 Dec 13;357(24):2482-94. Review.</citation>
    <PMID>18077812</PMID>
  </reference>
  <reference>
    <citation>O'Kennedy N, Crosbie L, van Lieshout M, Broom JI, Webb DJ, Duttaroy AK. Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans. Am J Clin Nutr. 2006 Sep;84(3):570-9.</citation>
    <PMID>16960171</PMID>
  </reference>
  <reference>
    <citation>Fuentes E, Forero-Doria O, Carrasco G, Maricán A, Santos LS, Alarcón M, Palomo I. Effect of tomato industrial processing on phenolic profile and antiplatelet activity. Molecules. 2013 Sep 17;18(9):11526-36. doi: 10.3390/molecules180911526.</citation>
    <PMID>24048285</PMID>
  </reference>
  <reference>
    <citation>Fuentes E, Pereira J, Alarcón M, Valenzuela C, Pérez P, Astudillo L, Palomo I. Protective Mechanisms of S. lycopersicum Aqueous Fraction (Nucleosides and Flavonoids) on Platelet Activation and Thrombus Formation: In Vitro, Ex Vivo and In Vivo Studies. Evid Based Complement Alternat Med. 2013;2013:609714. doi: 10.1155/2013/609714. Epub 2013 Sep 16.</citation>
    <PMID>24159349</PMID>
  </reference>
  <reference>
    <citation>Rodríguez-Azúa R, Treuer A, Moore-Carrasco R, Cortacáns D, Gutiérrez M, Astudillo L, Fuentes E, Palomo I. Effect of tomato industrial processing (different hybrids, paste, and pomace) on inhibition of platelet function in vitro, ex vivo, and in vivo. J Med Food. 2014 Apr;17(4):505-11. doi: 10.1089/jmf.2012.0243. Epub 2013 Dec 10.</citation>
    <PMID>24325459</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>December 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2016</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet Aggregation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

